Inclusion Criteria:
* Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.
* Have a body mass index within the range of 18.5 to 32.0 kilograms per square meter (kg/m\^2) (inclusive).
* Individuals of childbearing potential (IOCBP) are excluded from this trial.
* Individuals not of childbearing potential (INOCBP) may participate in this trial.
Exclusion Criteria:
* Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.
* Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.
* Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator.
* Participants with an estimated glomerular filtration rate \<90 mL/min/1.73 m2.
* Have a 12-lead Electrocardiogram (ECG) abnormality that, in the opinion of the investigator,
* increases the risks associated with participating in the study
* may confound ECG data analysis
* Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing.
* Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions.
* Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable)
* Show evidence of
* Human immunodeficiency virus (HIV) infection and/or positive human HIV antigen and/or antibodies
* hepatitis C and/or positive hepatitis C antibody
* hepatitis B and/or positive hepatitis B surface antigen.
* Have liver disease.
* Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment.
